The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells

SIMPLE SUMMARY: The current standard therapy of ovarian cancers comprises a reductive surgery followed by a combination of taxane-platinum-based primary chemotherapy. However, despite an initial positive response, patients in the advanced stage showed relapse within months or even weeks. Thus, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Raab, Monika, Rak, Marcel, Tesch, Roberta, Gasimli, Khayal, Becker, Sven, Knapp, Stefan, Strebhardt, Klaus, Sanhaji, Mourad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345098/
https://www.ncbi.nlm.nih.gov/pubmed/34359562
http://dx.doi.org/10.3390/cancers13153658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345098/
https://www.ncbi.nlm.nih.gov/pubmed/34359562
http://dx.doi.org/10.3390/cancers13153658

Ejemplares similares